Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells  Richard.

Slides:



Advertisements
Similar presentations
Volume 16, Issue 3, Pages (March 2008)
Advertisements

Mark M Metzstein, H.Robert Horvitz  Molecular Cell 
Blocking Sp1 Transcription Factor Broadly Inhibits Extracellular Matrix Gene Expression In Vitro and In Vivo: Implications for the Treatment of Tissue.
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Human mesangial cells express inducible macrophage scavenger receptor
Robert E. White, Richard Wade-Martins, Michael R. James 
Recent Developments in Retroviral-Mediated Gene Transduction
Volume 14, Issue 3, Pages (September 2006)
Volume 17, Issue 8, Pages (August 2009)
Demethylation of an NF-κB enhancer element orchestrates iNOS induction in osteoarthritis and is associated with altered chondrocyte cell cycle  M.C. de.
Volume 7, Issue 4, Pages (April 2003)
Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation1  Dr Xiong Z. Ruan, Zac Varghese, Stephen.
Improved system for helper-dependent adenoviral vector production
Claire Soudais, Sylvie Boutin, Eric J. Kremer  Molecular Therapy 
Volume 2, Issue 4, Pages (October 2000)
Complete Cure of Persistent Virus Infections by Antiviral siRNAs
Volume 25, Issue 6, Pages (June 2017)
Jason Park, Stephanie Schulz, Scott A. Waldman  Gastroenterology 
Volume 10, Issue 1, Pages (July 2004)
Volume 19, Issue 12, Pages (December 2011)
Minimal Purkinje Cell-Specific PCP2/L7 Promoter Virally Available for Rodents and Non- human Primates  Keisuke Nitta, Yasunori Matsuzaki, Ayumu Konno,
Volume 23, Issue 10, Pages (October 2015)
Volume 9, Issue 4, Pages (April 2004)
Cell-Type-Specific Control of Enhancer Activity by H3K9 Trimethylation
Volume 14, Issue 3, Pages (September 2006)
Volume 60, Issue 3, Pages (September 2001)
Andriana G Kotini, Michel Sadelain, Eirini P Papapetrou 
Kathrin Theil, Margareta Herzog, Nikolaus Rajewsky  Cell Reports 
Volume 3, Issue 2, Pages (February 2001)
Volume 37, Issue 6, Pages (March 2010)
Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy 
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases  Li Xu, Piming Zhao, Andrew Mariano, Renzhi.
Kailin Xu, Hong Ma, Thomas J. McCown, Inder M. Verma, Tal Kafri 
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Receptor-Targeted Gene Delivery Using Multivalent Phagemid Particles
CD46 Is a Cellular Receptor for Human Herpesvirus 6
MyoD Targets TAF3/TRF3 to Activate Myogenin Transcription
Volume 23, Issue 1, Pages (January 2015)
Molecular Therapy - Methods & Clinical Development
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Volume 12, Issue 5, Pages (November 2005)
Volume 10, Issue 4, Pages (October 2004)
Molecular Therapy - Nucleic Acids
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Volume 61, Issue 5, Pages (May 2002)
Assessing the Functional Characteristics of Synonymous and Nonsynonymous Mutation Candidates by Use of Large DNA Constructs  A.M. Eeds, D. Mortlock, R.
Volume 11, Issue 6, Pages (June 2005)
Volume 18, Issue 5, Pages (May 2010)
Volume 9, Issue 4, Pages (October 2017)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Volume 18, Issue 9, Pages (September 2010)
Transcriptional Control of SLC26A4 Is Involved in Pendred Syndrome and Nonsyndromic Enlargement of Vestibular Aqueduct (DFNB4)  Tao Yang, Hilmar Vidarsson,
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 18, Issue 2, Pages (February 2010)
Phase 1/2 Open-label Dose-escalation Study of Plasmid DNA Expressing Two Isoforms of Hepatocyte Growth Factor in Patients With Painful Diabetic Peripheral.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Progestins activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells  Michael D Mueller, M.D., Jean-Louis Vigne,
Molecular Therapy - Methods & Clinical Development
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Volume 17, Issue 12, Pages (June 2007)
Endogenous GATA Factors Bind the Core Sequence of the tetO and Influence Gene Regulation with the Tetracycline System  David J. Gould, Yuti Chernajovsky 
Volume 15, Issue 7, Pages (July 2007)
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating Factor 
Sequence-Modified Antibiotic Resistance Genes Provide Sustained Plasmid-Mediated Transgene Expression in Mammals  Jiamiao Lu, Feijie Zhang, Andrew Z.
Volume 8, Issue 2, Pages (August 2003)
Volume 3, Issue 4, Pages (April 2001)
Presentation transcript:

Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells  Richard Wade-Martins, Yoshinaga Saeki, E Antonio Chiocca  Molecular Therapy  Volume 7, Issue 5, Pages 604-612 (May 2003) DOI: 10.1016/S1525-0016(03)00060-1 Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Conversion of the LDLR BAC into infectious vectors. (A) Sequence analysis of a 135-kb BAC insert located the LDLR locus and confirmed the presence of all 18 exons (marked as vertical lines) and the native promoter region, including the sterol response elements (SREs). The BAC contains the 45-kb LDLR transcribed region flanked by approximately 45 kb of 5′ and 45 kb of 3′ sequence. (B) The two retrofitting constructs used to convert the BAC into infectious vectors. pHG contains the HSV-1 amplicon elements oris and pac. In addition pEHHG contains the latent origin of replication (oriP) and the EBNA-1 gene, both episomal retention elements from EBV. Molecular Therapy 2003 7, 604-612DOI: (10.1016/S1525-0016(03)00060-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 2 pHSV-LDLR and pHSV/EBV-LDLR efficiently deliver an intact, functional 135-kb insert by infection. (A) Plasmid rescue analysis of infected MRC-5V2 human fibroblast cells 48 h postinfection shows intact delivery and recovery of the 149- and 156-kb constructs in E. coli. (B) Infectious delivery of pHSV-LDLR and pHSV/EBV-LDLR to the ldlr-deficient CHO ldl−/−a7 cell line results in LDLR expression assayed by uptake of fluorescently labeled DiI-LDL. Molecular Therapy 2003 7, 604-612DOI: (10.1016/S1525-0016(03)00060-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 3 pHSV/EBV-LDLR restores specific LDLR function to wild-type levels in CHO ldl−/−a7 cells. (A) GFP reporter gene analysis shows very efficient pHSV/EBV-LDLR infection of CHO ldl−/−a7 cells. Control infections of pEHHG were performed at the same m.o.i. (B) Quantitation of specific LDLR activity by measuring LDL binding and uptake shows LDLR function to be restored to wild-type levels in CHO ldl−/−a7 cells 72 h postinfection. Nonspecific binding was determined in the presence of a 50-fold excess of unlabeled LDL and subtracted from total binding to give specific binding. Means are from three independent experiments, each performed in duplicate; error bars are +1 SEM. Molecular Therapy 2003 7, 604-612DOI: (10.1016/S1525-0016(03)00060-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 4 pHSV/EBV-LDLR is retained episomally and expressed long term in rodent cells. (A) Plasmid rescue recovers only intact pHSV/EBV-LDLR from two clonal CHO ldl−/−a7 lines. (B) The episomal pHSV/EBV-LDLR is maintained at a copy number of ∼10–17/cell. (C) pHSV/EBV-LDLR has restored the ability of the cells to take up DiI-LDL. (D) Quantitative analysis shows that the clonal cell lines have specific LDLR expression levels broadly similar to those of wild-type CHO cells. Nonspecific binding was determined in the presence of a 50-fold excess of unlabeled LDL and subtracted from total binding to give specific binding. Means are from three independent experiments, each performed in duplicate; error bars are +1 SEM. All the data shown for (A) to (D) were collected after 3 months of continuous culture. Molecular Therapy 2003 7, 604-612DOI: (10.1016/S1525-0016(03)00060-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 5 Infectious delivery and expression of the 135-kb LDLR genomic DNA locus in human FH patient primary fibroblasts. (A) Primary fibroblast cell lines FH-486 and FH-488 show negligible specific binding or uptake of LDL, compared to wild-type primary human fibroblasts (MRC-9). Nonspecific binding and internalization were determined in the presence of a 50-fold excess of unlabeled LDL. (B) Infection of FH primary fibroblasts by pHSV-LDLR and pHSV/EBV-LDLR is highly efficient, as assayed by GFP reporter gene expression. (C) Specific LDLR expression in FH fibroblasts following pHSV-LDLR and pHSV/EBV-LDLR infection. Means are from three independent experiments, each performed in duplicate; error bars are +1 SEM. Molecular Therapy 2003 7, 604-612DOI: (10.1016/S1525-0016(03)00060-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 6 Specific LDLR expression from the infectious genomic DNA vectors is repressed by elevated sterol levels. (A) Patient primary fibroblast FH-488 cells were infected with iBAC-LDLR vectors and LDL binding and uptake were assayed after incubation in the absence or presence of sterols (12 μg/ml cholesterol and 0.6 μg/ml 25-hydroxycholesterol). Nonspecific binding was determined in the presence of a 50-fold excess of unlabeled LDL and subtracted from total binding to give specific binding. Means are from three independent experiments, each performed in duplicate; error bars are +1 SEM. *P < 0.05 and **P < 0.01 by t test. (B) The presence of sterols did not alter the infectivity of the amplicons nor reporter gene (GFP) expression. Molecular Therapy 2003 7, 604-612DOI: (10.1016/S1525-0016(03)00060-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions